截至2026年1月12日收盘，何氏眼科(301103)报收于20.84元，上涨2.86%，换手率1.99%，成交量3.14万 手，成交额6458.06万元。 董秘最新回复 投资者： 请问何星儒何总，贵公司股价长期处于低位，对公司品牌带来极大负面影响，为何不积极回 购股份提升公司的市场价值呢？ 董秘： 尊敬的投资者您好，截止目前公司已累计回购股份2,722,719股。关于股份回购计划，公司管理 层将根据公司资金安排并结合实际经营情况及未来发展需求等多种因素考量，未来如有回购相关计划， 将严格按照法律法规及交易所规则，履行决策程序并及时披露相关信息。公司将继续做好经营管理，夯 实企业内在价值，坚持长期可持续发展战略、透明的信息披露与有效的投资者沟通，稳步推进资本市场 品牌建设，努力为投资者创造长期价值。谢谢！ 投资者： 董秘你好，公司长期大幅破发，投资者毫无获得感，作为辽宁地区知名企业，后续公司有什 么具体的稳定提升股价的措施吗？ 董秘： 尊敬的投资者您好，股价的波动受市场整体情绪、行业板块轮动、资金偏好等多重因素综合影 响。公司坚持聚焦主业，稳健经营，以投资者为本，通过不断完善公司治理，积极加强与国内外同领域 ...

证券日报网讯 1月8日，何氏眼科（301103）在互动平台回答投资者提问时表示，股价的波动受市场整 体情绪、行业板块轮动、资金偏好等多重因素综合影响。公司始终重视市值管理工作，坚持聚焦主业， 稳健经营，以投资者为本，通过不断完善公司治理、提升经营质量、合理规划现金分红、提高信息披露 和投资者关系管理水平，系统性推进市值管理工作，致力于实现公司内在价值与市场价值的动态平衡， 切实维护全体股东的长远利益。公司坚信，长期稳定的市值源于扎实的经营业绩与清晰的价值逻辑。未 来，公司坚持长期可持续发展战略、透明的信息披露与有效的投资者沟通，稳步推进资本市场品牌建 设，努力为投资者创造长期价值。 ...

证券日报网讯1月8日，何氏眼科（301103）在互动平台回答投资者提问时表示，公司管理层将根据公司 资金安排并结合实际经营情况及未来发展需求等多种因素考量，未来如有回购相关计划，将严格按照法 律法规及交易所规则，履行决策程序并及时披露相关信息。 ...

Core Viewpoint - He Eye Hospital is advancing in the field of gene therapy, focusing on hereditary eye diseases and offering a range of services including genetic testing and personalized risk screening [2] Group 1: Gene Therapy Initiatives - He Eye Hospital, led by renowned expert Professor Pang Jijing, has established a specialized clinic for hereditary eye diseases [2] - The clinic provides services such as genetic testing, diagnosis, treatment, personalized risk screening, and health management for hereditary eye disease patients and their families [2] Group 2: Business Developments - The company is progressing with the acquisition of overseas Medial Corporation, which is involved in stem cell exosome research [2] - The business scope of the acquisition includes the development of anti-aging products [2] - Current developments have not significantly impacted the company's main business operations or performance [2]

Group 1 - The core viewpoint of the news is the performance and financial details of He Eye Hospital Group, which saw a stock price increase of 1.29% to 19.69 CNY per share, with a total market capitalization of 3.112 billion CNY [1] - He Eye Hospital Group, established on October 15, 2009, and listed on March 22, 2022, primarily provides specialized ophthalmic diagnosis and treatment services, with revenue breakdowns including 30.24% from vision services, 24.16% from refractive surgery, and 13.68% from cataract treatment [1] - The company reported a trading volume of 8.6667 million CNY and a turnover rate of 0.36% [1] Group 2 - Among the top ten circulating shareholders of He Eye Hospital, the Rongtong Health Industry Flexible Allocation Mixed A/B fund reduced its holdings by 93,200 shares, now holding 2.7015 million shares, which is 2.22% of the circulating shares [2] - The Rongtong Health Industry Flexible Allocation Mixed A/B fund, established on December 25, 2014, has a current scale of 1.816 billion CNY, with a year-to-date return of 8.73% and a one-year return of 6.27% [2] - The fund manager, Wan Minyuan, has a tenure of 9 years and 130 days, with the best fund return during this period being 131.32% [3]

Core Viewpoint - The company, Liaoning He Eye Hospital Group Co., Ltd., is launching a shareholder reward program to express gratitude to its investors and establish a long-term, diverse shareholder return mechanism [1][5]. Group 1: Activity Content - The program includes personalized eye health service consultants for each participating shareholder, offering "full-process convenient services" [1]. - Discounts on optical products such as orthokeratology lenses, myopia management lenses, and frame glasses will be provided [1]. - Exclusive discounts on diagnostic projects including visual training, genetic testing, and meibomian gland massage therapy are part of the offerings [1]. - Shareholders will receive special discounts on myopia correction refractive surgeries [1]. - Aesthetic medical projects will also be included in the rewards [1]. - Customized eye health check-up plans will be available for shareholders [1]. Group 2: Participation Scope - The program is open to current shareholders, historical shareholders, and future investors, including direct relatives (spouse, parents, children) of the shareholders [2]. Group 3: Activity Locations - The activities will take place at the company's subsidiary hospitals and core city clinics [3]. Group 4: Activity Duration - The program will be executed long-term starting from the date of the announcement [4]. Group 5: Participation Method - More details about the activities will be available through the WeChat account "He Eye Investor Relations," with relevant content to be published on December 26, 2025 [5]. Group 6: Additional Notes - This initiative is a practical measure for the company to implement its shareholder return philosophy and express sincere gratitude for the long-term support and attention from shareholders [5].

Core Viewpoint - He Eye Hospital (301103.SZ) is celebrating its 30th anniversary by launching an "Investor Health Feedback Activity" to establish a long-term and diverse shareholder return mechanism, expressing gratitude to shareholders for their ongoing support and trust [1] Group 1: Investor Engagement - The company will provide each participating shareholder with a dedicated eye health service consultant to offer "full-process convenient services" [1] - Discounts will be available on optical products such as orthokeratology lenses, myopia management lenses, and frame glasses [1] - Exclusive discounts on diagnostic projects including eye-brain visual training, genetic testing, and meibomian gland massage therapy will be offered [1] Group 2: Surgical and Aesthetic Services - Shareholders will receive exclusive discounts on myopia correction refractive surgeries [1] - Aesthetic medical projects will also be included in the offerings [1] - Special eye health check-up plans will be available for shareholders [1]

Core Viewpoint - He Eye Hospital (301103.SZ) celebrates its 30th anniversary by launching an "Investor Health Feedback Activity" to establish a long-term and diverse shareholder return mechanism, expressing gratitude to shareholders for their ongoing support and trust [1] Group 1: Investor Engagement - The company provides each participating shareholder with a dedicated eye health service consultant to offer "full-process convenient services" [1] - Discounts on optical products such as orthokeratology lenses, myopia management lenses, and frame glasses are available for shareholders [1] - Exclusive discounts on diagnostic projects including eye-brain visual training, genetic testing, and meibomian gland massage treatment are offered [1] Group 2: Surgical and Aesthetic Services - Shareholders receive exclusive discounts on myopia correction refractive surgeries [1] - Aesthetic medical projects are included in the offerings for shareholders [1] - Special eye health check-up plans are available for participating shareholders [1]

证券代码：301103 证券简称：何氏眼科 公告编号：2025-053 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 辽宁何氏眼科医院集团股份有限公司（以下简称"公司"）成立三十周年之际， 为建立长效、多样的股东回报机制，感谢广大股东长期以来对公司的关注和支持， 为感谢投资者的长期信任，进一步形成传播眼健康、全民眼健康的良好氛围，公 司开展"投资者健康回馈活动"，现将本次活动内容公告如下： 一、活动内容 1、医院为每位参与活动的股东配备专属眼健康服务顾问，提供 "全流程便 捷服务"； 2、视光产品类优惠：角膜塑形镜、近视管理镜片、框架眼镜等； 3、诊疗项目专属优惠：眼脑视觉训练、基因检测项目、睑板腺按摩治疗等； 4、近视矫正屈光手术股东专属优惠； 5、医美项目； 辽宁何氏眼科医院集团股份有限公司 关于股东回馈活动的自愿性信息披露公告 公司下属分院及核心城市门诊。 四、活动时间 自本公告发布之 日起，长期执行。 五、参与方式 通过扫描下方二 维码报名参与。 6、眼健康检查专属方案。 二、参加活动的股东范围 包括现有股东、历史股东及未来投资者，股东本人及直系亲属 ...

Core Viewpoint - The resignation of Zhou Jinfeng, the company's director and board secretary, is noted, and the company is taking steps to ensure continuity in its operations and governance [1] Group 1: Management Changes - Zhou Jinfeng submitted a written resignation report due to personal reasons, effective immediately upon delivery [1] - Zhou will no longer hold any position within the company after his resignation [1] - The company’s general manager, He Xingru, will temporarily assume the duties of the board secretary until a new appointment is made [1] Group 2: Financial Performance - For the period from January to September 2025, the company reported revenue of 855 million yuan, a year-on-year decrease of 1.11% [1] - The net profit attributable to shareholders for the same period was 54 million yuan, reflecting a significant year-on-year increase of 232.18% [1] - The increase in net profit is attributed to the company's focus on enhancing medical services, optimizing the supply chain, and reducing operational costs through various measures [1]